JP Morgan Upgrades CAMP4 Therapeutics, Sets $9 Price Target

JP Morgan has upgraded its rating on CAMP4 Therapeutics Corporation (NasdaqGM: CAMP) to 'buy', setting a new price target of $9. This upgrade was announced on June 16, 2026, by analyst Anupam Rama, who sees potential for the biotechnology company.

Other Institutional Activity in CAMP4 Therapeutics

Janus Henderson Group PLC holds 6.3 million shares valued at about $27.9 million, maintaining its position. 5AM Venture Management, LLC also kept its stake steady with 5.9 million shares worth approximately $25.9 million. FMR LLC increased its holdings slightly by 15,189 shares, bringing its total to nearly 4.9 million shares valued at $21.8 million. Meanwhile, Balyasny Asset Management L.P. added 195,537 shares, now holding over 2.6 million shares valued at $11.6 million. Conversely, Enavate Sciences GP, LLC reduced its position by 844,905 shares, retaining around 2.2 million shares worth $9.7 million.

CAMP4 Therapeutics Stock Snapshot

Shares of CAMP4 Therapeutics Corporation are currently trading at $3.96. The company has a market capitalization of approximately $205.6 million. Although CAMP4 is not yet profitable, its forward P/E ratio is not meaningful due to negative earnings. The stock has experienced a 52-week low of $1.31 and a high of $7.75. The current 50-day moving average is $4.33, while the 200-day moving average stands at $4.21. The company maintains a strong liquidity position with a current ratio of 6.15 and a quick ratio of 5.97.

Recent Earnings

CAMP4 Therapeutics reported revenue of $3.93 million with a growth rate of 50.8%. Despite this, the company has a negative return on equity of -209.3% and no meaningful net margin due to its current loss-making status. The next earnings report is expected on August 12, 2025.

Insider Buying and Selling at CAMP4 THERAPEUTICS CORPORATION

Several insiders, including Douglas Williams, Andrew Schwab, and Steven Holtzman, each bought 28,000 shares of CAMP4 Therapeutics on June 10, 2026. These transactions were not part of any pre-arranged trading plans.

Analysts Set New Price Targets

On June 16, 2026, JP Morgan upgraded CAMP4 Therapeutics to 'buy' with a $9 price target. Previously, on June 10, 2026, Chardan Capital initiated coverage with a 'buy' rating and a $6.5 target. Earlier in the year, Rodman & Renshaw and Leerink Partners also issued 'buy' ratings with targets of $7 and $9, respectively. Overall, the consensus among six analysts is a 'strong buy' with an average price target of $7.92.

About CAMP4 Therapeutics Corporation

CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It focuses on developing RNA-based therapies to address various genetic disorders. The company's leading product candidate, CMP-001, is undergoing Phase 1/2 trials for urea cycle disorders. CAMP4 also has a candidate, CMP-002, targeting SYNGAP1-related disorders. Led by CEO Joshua Mandel-Brehm, CAMP4 employs 48 people.

Bottom Line

JP Morgan's upgrade of CAMP4 Therapeutics to a 'buy' with a $9 target highlights growing optimism about the company's prospects. The stock has seen significant insider buying, suggesting confidence from within. However, as CAMP4 is still in the development phase, investors should consider the inherent risks. Remember, 13F filings and analyst ratings are backward-looking and may not reflect current conditions.